Cancer related fatigue and the additive effect of treatment in the context of lymphoma: An analysis of the Lymphoma Coalition's 2022 Global Patient Survey.

Cancer related fatigue (CRF) continues to be a challenging phenomenon that is often under-reported and poorly understood. With etiologies in both disease and treatment manifesting as a symptom and a side-effect respectively, CRF is highly incident and presents a significant clinical problem that impacts survivorship. We conducted a survey to ascertain the patient reported incidence of symptoms and side-effects for people with lymphoma or chronic lymphocytic leukemia (CLL). We found that CRF was enhanced in those who received more intense therapies that coincided with more aggressive lymphoma subtypes. This data illuminates an unmet need amongst patients with lymphoma and provides an opportunity to further refine treatment regimens in order to reduce the burden of CRF in this vulnerable population.